In recent years, we have observed a high turnover in the development of new drugs, with a failure rate of almost 84% attributed to the low efficacy/toxicity benefit.

Three therapeutic areas are most affected by this decline:
— Cancer research (failure rate of 29.5%);
—Neurology (failure rate of 14%);
—And infectious diseases (failure rate of 9.5%).

Pharmaceutical companies attribute this reduction to the transposability between in vitro and in vivo studies, highlighting the need for new predictive models.